TNX 2300
Alternative Names: live viral vaccine-Kansas State University/Tonix Pharmaceuticals; TNX-2300Latest Information Update: 28 Aug 2024
At a glance
- Originator Kansas state university research foundation
- Developer Kansas state university research foundation; Tonix Pharmaceuticals Holding Corp
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA
- 13 Mar 2023 Tonix Pharmaceuticals has PCT applications pending for TNX 2300
- 15 Jul 2020 Kansas State University and Tonix Pharmaceuticals agreed to co-develop TNX 2300 COVD-19 vaccine